Switch theme
Sign up to access all valuation multiples
Coegin Pharma AB is a biotechnology company that focuses on the development of small molecule therapies for the treatment of inflammatory diseases such as cancer and kidney disease.
2019
3
Last FY Revenue n/a
Last FY EBITDA -$22.6M
$6.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Coegin Pharm achieved revenue of n/a and an EBITDA of -$22.6M.
Coegin Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Coegin Pharm valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | -$17K | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$22.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$26.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$26.7M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Coegin Pharm's stock price is EUR 0 (or $0).
Coegin Pharm has current market cap of EUR 7.4M (or $8.4M), and EV of EUR 5.6M (or $6.3M).
See Coegin Pharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.3M | $8.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Coegin Pharm has market cap of $8.4M and EV of $6.3M.
Coegin Pharm's trades at n/a EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate Coegin Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Coegin Pharm's P/E ratio is not available.
See valuation multiples for Coegin Pharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.4M | XXX | $8.4M | XXX | XXX | XXX |
| EV (current) | $6.3M | XXX | $6.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCoegin Pharm's revenue per employee in the last FY averaged n/a, while opex per employee averaged $8.7M for the same period.
Coegin Pharm's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Coegin Pharm's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Coegin Pharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $8.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Coegin Pharm acquired XXX companies to date.
Last acquisition by Coegin Pharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Coegin Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Coegin Pharm founded? | Coegin Pharm was founded in 2019. |
| Where is Coegin Pharm headquartered? | Coegin Pharm is headquartered in Germany. |
| How many employees does Coegin Pharm have? | As of today, Coegin Pharm has 3 employees. |
| Is Coegin Pharm publicy listed? | Yes, Coegin Pharm is a public company listed on FRA. |
| What is the stock symbol of Coegin Pharm? | Coegin Pharm trades under 7Z6 ticker. |
| When did Coegin Pharm go public? | Coegin Pharm went public in 2021. |
| Who are competitors of Coegin Pharm? | Similar companies to Coegin Pharm include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Coegin Pharm? | Coegin Pharm's current market cap is $8.4M |
| Is Coegin Pharm profitable? | Yes, Coegin Pharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
